About
Auerbach is the Founder, President, and CEO of Puma Biotechnology, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Previously, he founded Cougar Biotechnology and served as the company's President and CEO until the company's acquisition by Johnson & Johnson in 2009. Following the acquisition, Mr. Auerbach served as the Co-Chairman of the Integration Steering Committee at Cougar that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate, for the treatment of advanced prostate cancer. Prior to founding Cougar, Mr. Auerbach was a Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on oncology. He had primary responsibility for technical, scientific, and clinical due diligence as well as selection of biotechnology companies followed
Position in the VCSift Database
- • 9 investors hold the Founder, Chief Executive Officer & President role in VCSift. Alan H. Auerbach is one of them.
- • 2,641 investors are based in Los Angeles, California, United States.
Data sourced from 410,343 investor profiles. Updated June 2026.
Investment Focus
- Location
- Los Angeles, US
Contact Information
Find more investors like Alan
Search Investors